胃肠胰神经内分泌肿瘤

别名

GEP-NEN

近两年的全球研究 102L2

2024/10 起在 Europe PMC 检索所得，按发表时间倒序显示最近 20 篇。标题未译成中文——自动翻译需要接入 LLM 服务，尚未引入。

• 2026-09综述开放获取
  The Use of Adjunct Therapies with Surgery for Gastroenteropancreatic Neuroendocrine Tumors: Indications, Timing, and Outcomes
  Biomedicines · DOI · Europe PMC
• 2026-09综述开放获取
  Historical Evolution of Terminology and Current Classification of Neuroendocrine Neoplasms of the Larynx and Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms (MiNENs): A Narrative Review
  Diagnostics (Basel, Switzerland) · DOI · Europe PMC
• 2026-09综述
  T-cell engagers in small cell lung cancer
  Cancer · DOI · Europe PMC
• 2026-08开放获取
  Temporal trends in small-cell lung cancer trials registered on ClinicalTrials.gov: a cross-sectional analysis (1996-2025)
  Journal of thoracic disease · DOI · Europe PMC
• 2026-08综述开放获取
  Primary Biliary Neuroendocrine Tumors: A Systematic Review of Surgical Management, Oncologic Outcomes and Implications for Personalized Care
  Journal of personalized medicine · DOI · Europe PMC
• 2026-08病例报告开放获取
  Case Report: The role of nodal staging in periocular merkel cell carcinoma - lessons from three cases
  Frontiers in oncology · DOI · Europe PMC
• 2026-08综述
  Merkel cell carcinoma: A clinically oriented mini-review for dermatologists
  Dermatology (Basel, Switzerland) · DOI · Europe PMC
• 2026-08综述开放获取
  The role of FGFR signaling in SCLC and NSCLC: Current insights and therapeutic perspectives
  iScience · DOI · Europe PMC
• 2026-08病例报告开放获取
  Rapidly Enlarging Forearm Mass in a 74-Year-Old Male: A Case of Merkel Cell Carcinoma Presenting as a Soft Tissue Tumor
  Cureus · DOI · Europe PMC
• 2026-08综述开放获取
  Pathological Pathways of Olfactory Neuroblastoma: From Molecular Mechanisms to Targeted Therapy: A Narrative Review
  Cancers · DOI · Europe PMC
• 2026-08综述开放获取
  Emerging Therapeutic Strategies in Small-Cell Lung Cancer: From Adaptive Resistance to Precision Therapy
  Pharmaceuticals (Basel, Switzerland) · DOI · Europe PMC
• 2026-08系统综述开放获取
  Dietary Pattern and Risk of Thyroid Cancer: A Systematic Review
  Journal of human nutrition and dietetics : the official journal of the · DOI · Europe PMC
• 2026-07综述开放获取
  DLL3-directed immune redirection in small-cell lung cancer: a lineage-defined vulnerability that doubles as an escape route
  Frontiers in immunology · DOI · Europe PMC
• 2026-07综述开放获取
  Systemic therapy for gastroenteropancreatic neuroendocrine neoplasms: current landscape and future directions
  Therapeutic advances in medical oncology · DOI · Europe PMC
• 2026-07病例报告开放获取
  Neuroendocrine tumors of unknown primary: a case report and review of tumors with gastroenteropancreatic features
  Journal of gastrointestinal oncology · DOI · Europe PMC
• 2026-07综述开放获取
  Vitamin D Status and Gastroenteropancreatic Neuroendocrine Neoplasms: Biological Rationale, Clinical Associations and Limitations of Current Evidence
  Cancers · DOI · Europe PMC
• 2026-07综述开放获取
  Single-Cell and Spatial Transcriptomics Reframe the Immunosuppressive Microenvironment of Neuroendocrine Neoplasms
  Cancers · DOI · Europe PMC
• 2026-06病例报告开放获取
  Primary Merkel cell carcinoma of the submandibular region without cutaneous lesion: a case report
  Archives of craniofacial surgery · DOI · Europe PMC
• 2026-06综述开放获取
  From companion animals to patients: interspecies lessons in neuroendocrine oncology
  Frontiers in veterinary science · DOI · Europe PMC
• 2026-06
  Evaluating the Role of Chemotherapy in Addition to Radiotherapy for High-Risk Merkel Cell Carcinoma
  Medical sciences (Basel, Switzerland) · DOI · Europe PMC

在中国开展的临床试验 12L2

按病名在 ClinicalTrials.gov 检索、并校验研究中心含中国大陆而来。登记状态不等于现在真的能入组——务必按 NCT 号到原站核实，并与主治医生商量。

登记为可入组 4

• 招募中NCT05884255
  An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
  III 期 · 干预性 · 2023/07/06Jiangsu HengRui Medicine Co., Ltd.
  中国研究中心 2 个：Shanghai、Tianjin
• 招募中NCT06840821
  Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors
  I 期、II 期 · 干预性 · 2025/05/08Mainline Biosciences (Shanghai) Co., Ltd
  中国研究中心 1 个：Jinan
• 招募中NCT06784752
  Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
  III 期 · 干预性 · 2025/05/30Novartis Pharmaceuticals
  中国研究中心 2 个：Beijing、Shanghai
• 招募中NCT07165886
  Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors
  II 期、III 期 · 干预性 · 2025/08/29CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
  中国研究中心 1 个：Beijing

中国境外的在招试验 27L2

CT.gov 报告命中 27 项，此处取回并展示最近的 15 项。

• 尚未开始招募NCT07661420
  211At-MABG in Adults With Advanced Neuroendocrine Cancers
  I 期 · 干预性 · 2026/08/01University of Pennsylvania
  美国
• 招募中NCT07488923
  A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
  I 期 · 干预性 · 2026/06/23Moonlight Bio, Inc
  美国
• 招募中NCT07635316
  A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
  观察性 · 2026/06/12Novartis Pharmaceuticals
  美国
• 招募中NCT07278479
  Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
  I 期、II 期 · 干预性 · 2026/05/18Molecular Partners AG
  美国
• 招募中NCT06937905
  Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)
  III 期 · 干预性 · 2026/02/06Intergroupe Francophone de Cancerologie Thoracique
  法国
• 招募中NCT07165132
  Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
  I 期 · 干预性 · 2025/12/03RayzeBio, Inc.
  加拿大、美国
• 招募中NCT07006727
  Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
  I 期 · 干预性 · 2025/10/16Novartis Pharmaceuticals
  加拿大、韩国、美国
• 招募中NCT07150546
  Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.
  I 期 · 干预性 · 2025/10/14Emory University
  美国
• 招募中NCT07080242
  Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
  I 期 · 干预性 · 2025/04/28SystImmune Inc.
  美国
• 招募中NCT07302100
  Nutritional Status Assessment in Adult Patients Followed for Gastroenteropancreatic Neuroendocrine Tumors at Strasbourg University Hospital
  观察性 · 2024/12/12University Hospital, Strasbourg, France
  法国
• 招募中NCT06016855
  Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors
  IV 期 · 干预性 · 2024/05/31Vanderbilt-Ingram Cancer Center
  美国
• 招募中NCT04090034
  Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors
  观察性 · 2024/03/28Methodist Health System
  美国
• 招募中NCT06256705
  Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort
  不适用 · 干预性 · 2024/03/25Assistance Publique - Hôpitaux de Paris
  法国
• 招募中NCT05773274
  Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
  II 期 · 干预性 · 2024/01/12National Cancer Institute (NCI)
  加拿大、美国
• 招募中NCT05636618
  Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
  I 期、II 期 · 干预性 · 2023/09/27Perspective Therapeutics
  美国

外部标识与链接